NIAID Recent Advances in Addressing TB

A new “Perspective” in the Journal of Infectious Diseases by NIAID Director Anthony S. Fauci, MD, and other institute officials summarizes recent progress in improved TB diagnostics, therapeutic regimens and prevention approaches that made 2019 a “banner year” for TB...

NIAID Sponsors Phase I Clinical Trial of mAb CIS43LS Targeting Malaria

The National Institute of Allergy and Infectious Diseases (NIAID) has developed a monoclonal antibody (mAb) called mAb CIS43LS targeting malaria. They are now enrolling healthy adult volunteers in a Phase I clinical trial testing the safety and effectiveness of the...

Pin It on Pinterest